CATHERINE MARIE GHISLAINE GERARD,FREDERIC FRANCOIS EUGENE LEHMANN,JAMILA LOUAHED,PETER F. LEBOWITZ,SYLVIE LAQUERRE
申请号：
BR112014015703
公开号：
BR112014015703A2
申请日:
2012.12.19
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
A combination of anti-neoplastic agents that provides increased activity over monotherapy, or in some cases at least an unexpected lack of negative interaction. In particular, the drug combination that includes a MAGE-A3 immunotherapeutic, in combination with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and/or a MEK inhibitor, particularly N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy； -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof is described.
